|
MYO6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
1.355590E-02 |
| Normal-vs-Stage3 |
1.26919585952123E-11 |
| Normal-vs-Stage4 |
5.65190000023641E-07 |
| Stage1-vs-Stage2 |
1.148490E-02 |
| Stage1-vs-Stage3 |
5.254200E-01 |
| Stage1-vs-Stage4 |
2.034200E-01 |
| Stage2-vs-Stage3 |
9.755700E-03 |
| Stage2-vs-Stage4 |
5.837500E-03 |
| Stage3-vs-Stage4 |
3.851800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62458935193399E-12 |
| Normal-vs-AfricanAmerican |
1.161740E-04 |
| Normal-vs-Asian |
1.78663000000023E-05 |
| Caucasian-vs-AfricanAmerican |
2.615800E-01 |
| Caucasian-vs-Asian |
3.851600E-01 |
| AfricanAmerican-vs-Asian |
1.214610E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.20939933015529E-11 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
2.324800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(41-60Yrs) |
9.2370555648813E-14 |
| Normal-vs-Age(61-80Yrs) |
2.60660000028778E-07 |
| Normal-vs-Age(81-100Yrs) |
1.217520E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.162770E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.318650E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.901200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.644200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.114800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.552000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.250400E-02 |
| Classical-VS-Follicular |
1.62558855265615E-12 |
| Classical-VS-Other |
2.467200E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
8.33009999978707E-07 |
| Tall-VS-Other |
5.478300E-02 |
| Tall-VS-Normal |
3.92279999594791E-08 |
| Follicular-VS-Other |
1.856450E-01 |
| Follicular-VS-Normal |
4.832400E-02 |
| Other-VS-Normal |
8.876300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.04460021030673E-10 |
| Normal-vs-N1 |
2.00059999677649E-08 |
| N0-vs-N1 |
6.219100E-03 |
|
|
